Laboratory and clinical studies on SY5555

Yoshiro Sawae, Kaoru Okada, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Yoshiyuki Niho

Research output: Contribution to journalArticlepeer-review


We performed laboratory and clinical studies on SY5555, a new oral penem antibiotic, with the following results. 1. Antimicrobial activity The MICs of SY5555 for 239 strains of clinical isolates were compared with those of cefixime (CFIX), cefteram (CFTM), cefpodoxime (CPDX), cefaclor (CCL) and imipenem (IPM). Against gram-positive cocci, the antimicrobial activity of SY5555 was almost equivalent to that of IPM, and superior to those of other cephems. Against gram-negative rods, SY5555 was comparable to CFIX, CFTM and CPDX, but inferior to IPM. 2. Clinical efficacy Three patients with pneumonia, 1 with acute bronchitis and 1 with chronic bronchitis were treated with SY5555 at a daily dose of 300~900 mg for 5~22 days. Clinical response was good in 3, fair in 1 and poor in 1 patient. As adverse reactions, epigastralgia and elevation of GOT, ALP and γ-GTP were observed in one case.

Original languageEnglish
Pages (from-to)370-374
Number of pages5
Publication statusPublished - 1994

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Laboratory and clinical studies on SY5555'. Together they form a unique fingerprint.

Cite this